MODULAR NANOTRANSPORTERS CAPABLE OF BINDING WITH SARS-COV-2 VIRUS NUCLEOCAPSID PROTEIN INTO TARGET CELLS

Y. V. Khramtsov; Храмцов Ю. В.; A. V. Ulasov; Уласов А. В.; T. N. Lupanova; Лупанова Т. Н.; G. P. Georgiev; Георгиев Г. П.; A. S. Sobolev; Соболев А. С.

doi:10.31857/S2686738923700191

MODULAR NANOTRANSPORTERS CAPABLE OF BINDING WITH SARS-COV-2 VIRUS NUCLEOCAPSID PROTEIN INTO TARGET CELLS

Authors: Khramtsov Y.V.¹, Ulasov A.V.¹, Lupanova T.N.¹, Georgiev G.P.¹, Sobolev A.S.¹^,2
Affiliations:
1. Institute of Gene Biology, RAS
2. Lomonosov Moscow State University
Issue: Vol 510, No 1 (2023)
Pages: 259-262
Section: Articles
URL: https://rjmseer.com/2686-7389/article/view/651106
DOI: https://doi.org/10.31857/S2686738923700191
EDN: https://elibrary.ru/QHSOXH
ID: 651106

Cite item

Full Text

Open Access
Restricted Access

Access granted
Restricted Access

Subscription Access

Abstract

Based on the literature data, an antibody-like molecule, a monobody, was selected that is capable of interacting with the nucleocapsid protein (N-protein) of the SARS-CoV-2 virus with high affinity (dissociation constant 6.7 nM). We have previously developed modular nanotransporters (MNTs) to deliver various molecules to a selected compartment of target cells. In this work, a monobody to the N-protein of the SARS-CoV-2 virus was included in the MNT using genetic engineering methods. In this MNT, a site for the cleavage of the monobody from the MNT in endosomes was also introduced. It was shown by thermophoresis that the cleavage of this monobody from MNT by the endosomal protease cathepsin B leads to a 12-fold increase in the affinity of the monobody for the N-protein. Cellular thermal shift assay showed the ability of the obtained MNT to interact with the N-protein in A431 cells transfected with the SARS-CoV-2 N-protein fused to the mRuby3 fluorescent protein.

Keywords

SARS-CoV-2, modular nanotransporters, nucleocapsid protein, antibody-like molecules, monobody, thermophoresis, cellular thermal shift assay

References

Clercq E.D., Li G. // Clin Microbiol Rev. 2016. V. 29. P. 695–747. https://doi.org/10.1128/CMR.00102-15
Gebauer M., Skerra A. // Annu Rev Pharmacol Toxicol. 2020. V. 60. P. 391–415.
Surjit M., Lal S.K. // Infect Genet Evol. 2008. V. 8. P. 397–405.
Wu C., Zheng M. // Preprints. 2020. 2020020247.
Prajapat M., Sarma P., Shekhar N., et al. // Indian J Pharmacol. 2020. V. 52. P. 56.
Du Y., Zhang T., Meng X., et al. // Preprints. 2020.
Sobolev A.S. // Front Pharmacol. 2018. V. 9, 952.
Khramtsov Y.V., Vlasova A.D., Vlasov A.V., et al. // Acta Cryst. 2020. V. D76. P. 1270–1279.
Slastnikova T.A., Rosenkranz A.A., Khramtsov Y.V., et al. // Drug Des Devel Ther. 2017. V. 11. P. 1315–1334.
Li G., Li W., Fang X., et al. // Protein Expr Purif. 2021. V. 186.
Kern H.B., Srinivasan S., Convertine A.J., et al. // Mol Pharmaceutics. 2017. V. 14 (5). P. 1450–1459.
Khramtsov Y.V., Ulasov A.V., Lupanova T.N. et al. // Dokl Biochem Biophys. 2022. V. 506. P. 220–222.
Molina D.M., Jafari R., Ignatushchenko M., et al. // Science. 2013. V. 341. P. 84–87.
Liao H.-I., Olson C.A., Hwang S., et al. // J Biol Chem. 2009. V. 284. P. 17512–17520.